Ware_112807 - the company to halt a large and once...

Info iconThis preview shows pages 1–8. Sign up to view the full content.

View Full Document Right Arrow Icon
www.ascb.org INTRODUCTION TO HIV: 1 . Equilibrium vs. Non equilibrium Viruses 2. Structure of the retrovirus, HIV 3. Re visit the “central dogma” 4. HIV life cycle 5. Infection statistics and health outcomes
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
www.ascb.org
Background image of page 2
www.ascb.org
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
CENTRAL DOGMA of MOLECULAR BIOLOGY UPDATED CENTRAL DOGMA 1970 REVERSE TRANSCRIPTION by the enzyme, reverse transcriptase Modified from www.ascb.org
Background image of page 4
www.ascb.org
Background image of page 5

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
www.ascb.org
Background image of page 6
Part 2: “Why Gene Therapy Might be a Reasonable Tool for Attacking HIV” by Dr. David Baltimore www.ascb.org ( iBioseminar series)
Background image of page 7

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
News in Brief Nature 449 , 390 (27 September 2007) | doi:10.1038/449390c; Published online 26 September 2007 HIV vaccine failure prompts Merck to halt trial An HIV vaccine being developed by Merck has apparently failed, causing
Background image of page 8
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: the company to halt a large and once promising clinical trial last week. Merck's STEP vaccine used a mixture of components from three weakened adenoviruses to carry three synthetically produced HIV genes. The hope was that each gene would stimulate an immune response against the virus, as earlier trials had suggested. The latest trial began in 2004 and enrolled 3,000 people considered to be at high risk of infection. But a group of 741 volunteers who received the vaccine saw 24 HIV infections, compared with the control group of 762 people who saw 21 infections. Furthermore, the vaccine did not reduce the amount of HIV in the bloodstream of those infected....
View Full Document

This note was uploaded on 03/09/2008 for the course BIOS 95 taught by Professor Varies during the Spring '08 term at Lehigh University .

Page1 / 8

Ware_112807 - the company to halt a large and once...

This preview shows document pages 1 - 8. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online